BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24835529)

  • 21. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
    Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
    Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic viruses against cancer stem cells: A promising approach for gastrointestinal cancer.
    Huang F; Wang BR; Wu YQ; Wang FC; Zhang J; Wang YG
    World J Gastroenterol; 2016 Sep; 22(35):7999-8009. PubMed ID: 27672294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Measles virus: a future therapeutic agent in oncology?].
    Touchefeu Y; Schick U; Harrington KJ
    Med Sci (Paris); 2012 Apr; 28(4):388-94. PubMed ID: 22549866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses.
    Weiland T; Lampe J; Essmann F; Venturelli S; Berger A; Bossow S; Berchtold S; Schulze-Osthoff K; Lauer UM; Bitzer M
    Int J Cancer; 2014 Jan; 134(1):235-43. PubMed ID: 23797800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic potential of oncolytic measles virus: promises and challenges.
    Galanis E
    Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.
    Bach P; Abel T; Hoffmann C; Gal Z; Braun G; Voelker I; Ball CR; Johnston IC; Lauer UM; Herold-Mende C; Mühlebach MD; Glimm H; Buchholz CJ
    Cancer Res; 2013 Jan; 73(2):865-74. PubMed ID: 23293278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
    Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
    Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential and clinical translation of oncolytic measles viruses.
    Robinson S; Galanis E
    Expert Opin Biol Ther; 2017 Mar; 17(3):353-363. PubMed ID: 28129716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mathematical modeling of cancer radiovirotherapy.
    Dingli D; Cascino MD; Josić K; Russell SJ; Bajzer Z
    Math Biosci; 2006 Jan; 199(1):55-78. PubMed ID: 16376950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Personalized Oncolytic Therapy: The Next Step Toward the Successful Clinical Application of Vaccine-Strain Measles Viruses for Cancer Therapy?
    Peikert T
    J Thorac Oncol; 2020 May; 15(5):689-691. PubMed ID: 32340675
    [No Abstract]   [Full Text] [Related]  

  • 32. Dynamics of multiple myeloma tumor therapy with a recombinant measles virus.
    Dingli D; Offord C; Myers R; Peng KW; Carr TW; Josic K; Russell SJ; Bajzer Z
    Cancer Gene Ther; 2009 Dec; 16(12):873-82. PubMed ID: 19498461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scientists are harnessing viruses to treat tumours.
    Brown C
    Nature; 2020 Nov; 587(7835):S60-S62. PubMed ID: 33239805
    [No Abstract]   [Full Text] [Related]  

  • 34. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.
    Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM
    Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. United virus: the oncolytic tag-team against cancer!
    Le Boeuf F; Bell JC
    Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma.
    Lei W; Wang S; Yang C; Huang X; Chen Z; He W; Shen J; Liu X; Qian W
    Sci Rep; 2016 Aug; 6():32174. PubMed ID: 27552933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.
    Liu C; Russell SJ; Peng KW
    Mol Ther; 2010 Jun; 18(6):1155-64. PubMed ID: 20234340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translational research in oncolytic measles virotherapy: early discoveries and future steps.
    Msaouel P; Opyrchal M; Galanis E
    Future Microbiol; 2011 Feb; 6(2):125-8. PubMed ID: 21366411
    [No Abstract]   [Full Text] [Related]  

  • 39. Viral Therapy Gets Personal: A Potential Gene Signature to Predict Susceptibility to Measles Virus Oncolysis.
    Forsyth PA; Abate-Daga D
    J Natl Cancer Inst; 2018 Oct; 110(10):1139-1140. PubMed ID: 29757401
    [No Abstract]   [Full Text] [Related]  

  • 40. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.
    Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D
    Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.